Advent International, a Boston-based global private equity investor, has named James Mullen as an operating partner.

Mullen will play a key role in building out Advent’s pharmaceutical and pharma services business, working with the firm’s healthcare investment team and the management teams of its portfolio companies. He brings 40 years of biopharma industry experience, including pharmaceutical and biotech manufacturing experience. Mullen currently serves as the executive chairman of Editas Medicine, a genome editing company, where he previously served as the company’s president and CEO. He also served as the CEO and director of Patheon, a pharmaceutical and manufacturing organization serving the pharmaceutical and biotechnology sectors, and CEO of Biogen Inc., a biotechnology company focused on the discovery and treatment of neurological diseases.

“His knowledge and expertise will enhance our ability to identify and partner with industry-leading pharmaceutical and pharma services companies across contract manufacturing, commercialization, and research that can create value for patients through cutting-edge technology,” says John Maldonado, managing partner at Advent.